Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study

NCT06059495 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma - GEJ
Gastric Adenocarcinoma

Interventions

DRUG: Dostarlimab

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group